![](https://investorshub.advfn.com/uicon/81806.png?cb=1635633872)
Wednesday, February 06, 2008 7:13:01 AM
Wednesday February 6, 6:00 am ET
First-Line Treatment for Patients at Risk for Skin Cancer Evaluated for Potential Effectiveness for Wide Array of Dermatologic Needs
WILMINGTON, MASSACHUSETTS--(MARKET WIRE)--Feb 6, 2008 -- DUSA Pharmaceuticals, Inc. (NASDAQ GM: DUSA) -
Photodynamic Therapy (PDT) was featured as a key topic at the 66th Annual American Academy of Dermatology (AAD) Meeting in San Antonio, Texas. More than 25 presentations and posters by prominent investigators addressed PDT, focusing on the therapy's benefits and clinical developments, including the FDA-approved use of aminolevulinic acid (ALA) PDT for the treatment of mild to moderate actinic keratoses (AKs) of the face or scalp, as well as investigational uses for skin cancer, acne and numerous other skin conditions.
http://biz.yahoo.com/iw/080206/0358052.html
Greenlite Ventures Completes Agreement with No Limit Technology • GRNL • Jul 19, 2024 10:00 AM
VAYK Expects Revenue from First Airbnb Property Starting from August • VAYK • Jul 18, 2024 9:00 AM
North Bay Resources Acquires Mt. Vernon Gold Mine, Sierra County, California, with Assays up to 4.8 oz. Au per Ton • NBRI • Jul 18, 2024 9:00 AM
Nightfood Holdings Signs Letter of Intent for All-Stock Acquisition of CarryOutSupplies.com • NGTF • Jul 17, 2024 1:00 PM
Kona Gold Beverages Reaches Out to Largest Debt Holder for Debt Purchase Negotiation • KGKG • Jul 17, 2024 9:00 AM
Avant Technologies Welcomes Back Former CEO with Eye Toward Future Growth and Expansion • AVAI • Jul 17, 2024 8:00 AM